IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Rare Kidney Diseases
IgA Nephropathy: From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read MoreRisk Factors for Rapid Disease Progression of ADPKD
In this presentation rapid disease progression of autosomal dominant polycystic kidney disease (ADPKD) will be defined. Read MoreRisk Factors for Rapid Disease Progression of ADPKD
In this presentation rapid disease progression of autosomal dominant polycystic kidney disease (ADPKD) will be defined. Read MoreIgA Nephropathy – From Pathogenesis to Current Management
Featuring Marla Dallal, PharmD, RPH is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Read MoreIgA Nephropathy – From Pathogenesis to Current Management
Featuring Abigail Yancey, PharmD, FCCP, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Read MoreIgA Nephropathy – From Pathogenesis to Current Management
Featuring Dr Shiravanthe is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Read MoreIgA Nephropathy – From Pathogenesis to Current Management
In this presentation, we will discuss the important role of imaging in diagnosis and prognosis of ADPKD, including measuring TKV, looking at complications and more. Read MoreIgA Nephropathy – From Pathogenesis to Current Management
Featuring Dr Sachin Hajarnis, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Read MoreUnderstanding The IgA Nephropathy Patient Journey
Learn about the IgA Nephropathy patient journey directly from an IgAN patient and nephrology healthcare provider, Kelly Chen. Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
